Recombination and Transmission Studies with Influenza Virus.
Annual progress rept. 1 Jun 71-1 Aug 72,
MOUNT SINAI SCHOOL OF MEDICINE NEW YORK
Pagination or Media Count:
During the past year studies of recombinant influenza virus vaccines have continued with a view to improvement of standard vaccines and the introduction of a new principle of mono-antigenic immunization. X-32, a recombinant virus containing the Hong Kong neuraminidase but the AEquil hemagglutinin which is irrelevant to contemporary human experience has been used in the production of a conventional formalin inactivated influenza vaccine. In preliminary studies in volunteers, parenteral administration of X-32 vaccine has been shown to reduce significantly the occurrence of systemic symptoms and fever. It was concluded that the approach is promising and it is desired to extend these studies into the field. In other studies, two new recombinants, X-35 and X-36, were produced which are analogous to the X-31 strain now in use in contemporary vaccines in having acquired the high-yielding characteristic from the PR8 virus. These recombinants are derived from recent isolates of Hong Kong virus which have shown significant antigenic drift from the 1968 strains. Both recombinant viruses are markedly superior to the wild type viruses in yield and hence are vaccine candidate strains.